This database contains 83 studies, archived under the term: "indans"
Click here to filter this large number of results.
Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size
Román, Gustavo C.,
Salloway, Stephen,
Black, Sandra E.,
Royall, Donald R.,
DeCarli, Charles,
Weiner, Michael W.,
Moline, Margaret,
Kumar, Dinesh,
Schindler, Rachel,
Posner, Holly
Background and Purpose: We sought to assess the efficacy and safety of donepezil in patients with vascular dementia (VaD) fulfilling National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences criteria.; Methods: This international, multicenter, 24-week trial was conducted from March 2003 to August 2005. Patients (N=974; mean age, 73.0 […]
Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer’s disease
Matsuda, Osamu,
Shido, Emi,
Hashikai, Ayako,
Shibuya, Haruka,
Kouno, Mitsue,
Hara, Chizuko,
Saito, Masahiko
Background: Acetylcholinesterase inhibitors (i.e. donepezil) are known to benefit Alzheimer’s disease (AD) patients. However, the combined effects of acetylcholinesterase and cognitive stimulation therapy (CST) are still debated. The present study examined their combined effects on the progression of cognitive decline in AD.; Methods: The present study was a non-randomized controlled study and included two groups […]
Comparative cardiovascular safety of dementia medications: a cross-national study
Fosbøl, Emil L.,
Peterson, Eric D.,
Holm, Ellen,
Gislason, Gunnar H.,
Zhang, Yinghong,
Curtis, Lesley H.,
Køber, Lars,
Iwata, Isao,
Torp-Pedersen, Christian,
Setoguchi, Soko
Objectives: To compare the cardiovascular safety of currently marketed dementia medications in new users in the United States and Denmark.; Design: Retrospective cohort study.; Setting: Nationally representative sample of Medicare beneficiaries from 2006 through 2009 and nationwide Danish administrative registries from 1997 through 2007.; Participants: Individuals treated with a dementia medication aged 65 and older.; […]
Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease
Zhong, Yuan,
Zheng, Xueli,
Miao, Ya,
Wan, Lili,
Yan, Hong,
Wang, Beiyun
Background: The aim of this study was to evaluate the effect of CYP2D6*10 and APOE polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of donepezil in patients with mild-to-moderate Alzheimer’s disease (AD).; Methods: A total of 110 Chinese AD patients participated in this study. Patients were treated with 5 to 10 mg of […]
The effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer’s disease treated in routine clinical practice in Spain
López-Pousa, S.,
Bermejo-Pareja, F.,
Frank, A.,
Hernández, F.,
León, T.,
Rejas-Gutiérrez, J.
Aims: Our aim was to perform a secondary analysis of a 12-month-long, non-blind, multi-centre prospective cost-of-illness study. The analysis assessed the effect of donepezil on cognitive functioning and the performance of patients with possible or probable Alzheimer’s disease, compared to that of other drugs for dementia.; Patients and Methods: A sample of 700 patients took […]
A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease
Akhondzadeh, Shahin,
Shafiee Sabet, Mehdi,
Harirchian, Mohammad Hossein,
Togha, Mansoreh,
Cheraghmakani, Hamed,
Razeghi, Soodeh,
Hejazi, Seyyed Shamssedin,
Yousefi, Mohammad Hossein,
Alimardani, Roozbeh,
Jamshidi, Amirhossein,
Rezazadeh, Shams-Ali,
Yousefi, Aboulghasem,
Zare, Farhad,
Moradi, Atbin,
Vossoughi, Ardalan
Rationale: There is increasing evidence to suggest the possible efficacy of Crocus sativus (saffron) in the management of Alzheimer’s disease (AD).; Objective: The purpose of the present investigation was to assess the efficacy of C. sativus in the treatment of patients with mild-to-moderate AD.; Methods: Fifty-four Persian-speaking adults 55 years of age or older who […]
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer’s disease – a multicentre RCT
Jones, Rob,
Sheehan, Bart,
Phillips, Patrick,
Juszczak, Ed,
Adams, Jessica,
Baldwin, Ashley,
Ballard, Clive,
Banerjee, Sube,
Barber, Bob,
Bentham, Peter,
Brown, Richard,
Burns, Alistair,
Dening, Tom,
Findlay, David,
Gray, Richard,
Griffin, Mary,
Holmes, Clive,
Hughes, Alan,
Jacoby, Robin,
Johnson, Tony,
Jones, Roy,
Knapp, Martin,
Lindesay, James,
McKeith, Ian,
McShane, Rupert,
Macharouthu, Ajay,
O'Brien, John,
Onions, Caroline,
Passmore, Peter,
Raftery, James,
Ritchie, Craig,
Howard, Rob
Background: Alzheimer’s disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia […]
Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice
Hayashi, Yoshihito,
Ishida, Yasushi,
Inoue, Teruhiko,
Udagawa, Mitsutaka,
Takeuchi, Kouzou,
Yoshimuta, Hirofumi,
Kiue, Kouichirou,
Ninomiya, Yoshimasa,
Kawano, Jiro,
Sameshima, Tetsuro,
Kawahara, Takashi,
Goto, Isamu,
Shudo, Kenji,
Kurayama, Shigeki,
Nakamura, Jungo,
Okahara, Kazunori,
Mitsuyama, Yoshio
The efficacy and safety of the kampo medicine Yokukansan (YKS, TJ-54) in the treatment of behavioral and psychological symptoms of dementia (BPSD) were investigated in patients with Alzheimer’s disease (AD) in an open-label study. This study included 26 patients who had been diagnosed as having AD and were not treated with donepezil hydrochloride. These patients […]
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study
Farlow, Martin R.,
Salloway, Stephen,
Tariot, Pierre N.,
Yardley, Jane,
Moline, Margaret L.,
Wang, Qin,
Brand-Schieber, Elimor,
Zou, Heng,
Hsu, Timothy,
Satlin, Andrew
Background: Currently approved Alzheimer’s disease (AD) treatments have been reported to provide symptomatic benefit, without proven impact on clinical progression. We hypothesized that the loss of initial therapeutic benefit over time may be mitigated by higher doses of a cholinesterase inhibitor.; Objective: The aim of this study was to determine the effectiveness and tolerability of […]